Syra Health Corp. SYRA
0.88
0.02
2.33%
as of 25 Sep
- Market cap
- $1.1M
- P/E
- 90.0×
Follow SYRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.15 | 0.39 | 0.97 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(3.69) | (14.42) | (3.05) | (22.35) | (22.35) |
P/B ratio |
0.51 | 1.08 | 1.34 | 18.50 | 18.50 |
Price to Tangible BV |
0.51 | 1.08 | 1.34 | 18.50 | 18.50 |
EV/Sales |
0.17 | 0.31 | 0.70 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.70) | (0.84) | (1.39) | (4.83) | (4.83) |
EV/FCF |
(2.66) | (0.83) | (1.38) | (4.61) | (4.61) |
Quick Ratio |
3.75 | 5.01 | 4.83 | 0.78 | 0.80 |
Current Ratio |
4.06 | 5.47 | 5.25 | 0.92 | 0.84 |
Net Debt/EBITDA |
1.83 | 0.65 | 1.16 | (0.36) | 32.26 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 32.36% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 1.06 | 0.00 |
Asset Turnover |
2.24 | 1.86 | 1.52 | 3.93 | 0.00 |
Operating CF/Net income |
0.50 | 0.78 | 0.94 | 1.06 | 26.73 |
Capex/Depreciation |
0.00 | (0.18) | (0.31) | (4.20) | (31.50) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (36.02%) | (109.09%) | (124.42%) | (602.62%) | 0.00% | |
| (27.78%) | (87.40%) | (81.14%) | (148.31%) | 0.00% | |
ROIC |
(116.90%) | (486.97%) | (246.18%) | (89.62%) | 0.00% |
Return on Tangible Assets |
(43.28%) | (135.88%) | (74.39%) | 29,833.80% | 5.15% |
Average Days of Receivables |
46.39 | 31.13 | 73.54 | 78.04 | 67.46 |
Research and Development Expense of Revenue |
0.94% | 7.33% | 4.35% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
35.51% | 52.17% | 62.09% | 37.39% | 24.01% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.36% | 0.75% | 0.59% | 0.05% | 0.00% |
Graham Net Nets |
1.93 | 0.82 | 0.72 | 0.11 | 0.11 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(83.67%) | (131.71%) | (54.89%) | (17.50%) | (17.50%) |
Free Cash Flow Yield |
(42.49%) | (95.06%) | (51.71%) | (22.94%) | (22.94%) |
Revenue per Share |
0.61 | 1.06 | 1.13 | 1.85 | 1.69 |
Operating CF per Share |
(0.04) | (0.39) | (0.57) | (0.74) | (0.11) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | (0.01) |
Free Cash Flow per Share |
(0.04) | (0.39) | (0.57) | (0.78) | (0.11) |
Cash per Share |
0.14 | 0.32 | 0.67 | 0.00 | 0.12 |
Shareholders Equity per Share |
0.18 | 0.38 | 0.82 | 0.23 | (0.01) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.18 | 0.38 | 0.82 | 0.23 | (0.01) |
Free Cash Flow |
(0.45) | (2.94) | (2.77) | (2.37) | (0.09) |
Working Capital |
2.06 | 2.74 | 3.87 | (0.12) | (0.07) |
Capital Expenditures |
0.00 | (0.01) | (0.02) | (0.12) | (0.01) |
Net Current Asset Value |
2.06 | 2.55 | 3.87 | (0.18) | (0.16) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
Net Profit Margin |
(12.40%) | (47.10%) | (53.28%) | (37.71%) | (0.23%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
2.93 | 2.30 | 0.62 | 0.26 | 0.03 |
Cash ROIC |
(12.25%) | (56.11%) | (38.91%) | (160.97%) | (101.51%) |
Accounts Receivable Turnover |
9.04 | 8.91 | 4.77 | 7.69 | 0.00 |
Accounts Payable Turnover |
27.14 | 22.42 | 9.17 | 19.28 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
19.07 | 5.87 | 41.19 | 34.64 | 14.94 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.80 | 0.90 | 1.16 | 0.73 | — |
Average Payables |
0.17 | 0.28 | 0.45 | 0.24 | — |
Average Assets |
3.23 | 4.30 | 3.62 | 1.43 | — |
Average Common Equity |
2.49 | 3.45 | 2.36 | 0.35 | — |
Columns are period end dates